Competitive Density Analysis

Trial activity, Phase 3 concentration, and competitive dynamics by indication

Current Metrics: Based on ClinicalTrials.gov data (active trials, phases, sponsors).

Future Enhancement: True "white space" analysis (trials vs approved drugs) requires mapping FDA-approved drugs to our indication taxonomy. FDA labels use specific terms like "HER2+ metastatic breast carcinoma" while our taxonomy uses broader categories like "Breast Cancer". This mapping is in progress.

Highest Trial Activity

Most active indications by total trial count

Indication	TA	Active Trials	Phase 3	Phase 2	Sponsors
Rheumatoid Arthritis	Immunology	3887	871	1988	15
Ankylosing Spondylitis	Immunology	3496	801	1797	15
Solid Tumor (Advanced)	Oncology	3327	328	1738	15
Myocardial Infarction	Cardiovascular	1633	383	745	15
Non-Hodgkin Lymphoma	Oncology	1447	163	930	15
Breast Cancer	Oncology	1421	293	850	15
NSCLC	Oncology	1393	267	869	15
Colorectal Cancer	Oncology	1082	174	709	15
ALL	Oncology	1018	150	613	15
Erectile Dysfunction	Urology	861	203	382	15
Prostate Cancer	Oncology	857	153	534	15
AML	Oncology	649	71	351	15
Multiple Myeloma	Oncology	648	103	388	15
Pancreatic Cancer	Oncology	632	69	410	15
Hepatocellular Carcinoma	Oncology	596	91	369	15

Late-Stage Concentration

Highest Phase 3 activity (near-term competitive pressure)

Indication	TA	Phase 3	% of Trials	Active	Sponsors
Rheumatoid Arthritis	Immunology	871	22%	3887	15
Ankylosing Spondylitis	Immunology	801	23%	3496	15
Myocardial Infarction	Cardiovascular	383	23%	1633	15
Solid Tumor (Advanced)	Oncology	328	10%	3327	15
Breast Cancer	Oncology	293	21%	1421	15
NSCLC	Oncology	267	19%	1393	15
Erectile Dysfunction	Urology	203	24%	861	15
Colorectal Cancer	Oncology	174	16%	1082	15
Non-Hodgkin Lymphoma	Oncology	163	11%	1447	15
Prostate Cancer	Oncology	153	18%	857	15
ALL	Oncology	150	15%	1018	15
Stroke	Cardiovascular	145	41%	352	15

Concentrated Markets

Few sponsors running many trials (potential dominance or acquisition targets)

Indication	TA	Trials/Sponsor	Active	Sponsors
Rheumatoid Arthritis	Immunology	259.1	3887	15
Ankylosing Spondylitis	Immunology	233.1	3496	15
Solid Tumor (Advanced)	Oncology	221.8	3327	15
Myocardial Infarction	Cardiovascular	108.9	1633	15
Non-Hodgkin Lymphoma	Oncology	96.5	1447	15
Breast Cancer	Oncology	94.7	1421	15
NSCLC	Oncology	92.9	1393	15
Colorectal Cancer	Oncology	72.1	1082	15
ALL	Oncology	67.9	1018	15
Erectile Dysfunction	Urology	57.4	861	15

Fragmented Markets

Many sponsors competing (crowded, potentially commoditized)

Indication	TA	Sponsors	Active	Phase 3
Rheumatoid Arthritis	Immunology	15	3887	871
Ankylosing Spondylitis	Immunology	15	3496	801
Solid Tumor (Advanced)	Oncology	15	3327	328
Myocardial Infarction	Cardiovascular	15	1633	383
Breast Cancer	Oncology	15	1421	293
Non-Hodgkin Lymphoma	Oncology	15	1447	163
NSCLC	Oncology	15	1393	267
COVID-19	Infectious Disease	15	187	59
Erectile Dysfunction	Urology	15	861	203
ALL	Oncology	15	1018	150

Showing top indications in each category

Upgrade to Pro for full competitive density analysis across 140 indications

See Pro Features

Methodology

Data Source: ClinicalTrials.gov (Phase 2-4 interventional drug trials, 2015+)

Active Trials: Status = Recruiting, Active, or Enrolling by Invitation

Trials/Sponsor: Average trials per company in that indication. Higher = concentrated market.

Phase 3 %: Proportion of active trials in Phase 3. Higher = more near-term competitive pressure.